IN2014DN03429A - - Google Patents

Info

Publication number
IN2014DN03429A
IN2014DN03429A IN3429DEN2014A IN2014DN03429A IN 2014DN03429 A IN2014DN03429 A IN 2014DN03429A IN 3429DEN2014 A IN3429DEN2014 A IN 3429DEN2014A IN 2014DN03429 A IN2014DN03429 A IN 2014DN03429A
Authority
IN
India
Prior art keywords
inhibitor
matrix
allergene
whereon
adsorbed
Prior art date
Application number
Other languages
English (en)
Inventor
Thomas Grunwald
WEBER Carsten B SCHMIDT
Original Assignee
Pls Design Gmbh
Helmholtz Zentrum München Forschungszentrum Für Gesundheit Und Umwelt Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pls Design Gmbh, Helmholtz Zentrum München Forschungszentrum Für Gesundheit Und Umwelt Gmbh filed Critical Pls Design Gmbh
Publication of IN2014DN03429A publication Critical patent/IN2014DN03429A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN3429DEN2014 2011-11-23 2012-11-23 IN2014DN03429A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11075261.5A EP2596802A1 (en) 2011-11-23 2011-11-23 Pharmaceutical composition for treatment of allergic reactions
PCT/EP2012/004884 WO2013075846A1 (en) 2011-11-23 2012-11-23 Pharmaceutical composition for treatment of allergic reactions

Publications (1)

Publication Number Publication Date
IN2014DN03429A true IN2014DN03429A (enrdf_load_stackoverflow) 2015-06-05

Family

ID=47358079

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3429DEN2014 IN2014DN03429A (enrdf_load_stackoverflow) 2011-11-23 2012-11-23

Country Status (6)

Country Link
US (2) US20140335162A1 (enrdf_load_stackoverflow)
EP (1) EP2596802A1 (enrdf_load_stackoverflow)
CN (1) CN104039349A (enrdf_load_stackoverflow)
BR (1) BR112014012277A2 (enrdf_load_stackoverflow)
IN (1) IN2014DN03429A (enrdf_load_stackoverflow)
WO (1) WO2013075846A1 (enrdf_load_stackoverflow)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2813242A1 (en) * 2013-06-13 2014-12-17 PLS-Design GmbH Low molecular weight immune-modulators as adjuvants for specific immunotherapy
EP2918262B1 (en) * 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
MX391015B (es) * 2014-12-24 2025-03-21 Neximmune Inc Composiciones de nanoparticulas y usos de las mismas
CN105727371B (zh) * 2016-01-25 2019-04-09 北京天助畅运医疗技术股份有限公司 腹壁疝修补材料
AU2017258097B2 (en) 2016-04-27 2019-10-24 Abbvie Inc. Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodies
CN107669638B (zh) * 2017-10-23 2020-05-22 华南理工大学 一种peg-pcl-peg三嵌段共聚物修饰的羟基积雪草苷脂质体及其应用
US20240270819A1 (en) * 2020-04-22 2024-08-15 Elanco Us Inc. Il4/il13 receptor molecules for veterinary use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
DE4137333A1 (de) 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
TR199802591T2 (xx) 1996-06-14 1999-04-21 Bayer Corporation T-H�cresi se�ici interl�kin-4 agonistleri
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
KR20010030891A (ko) 1997-10-03 2001-04-16 마크로메드 인코퍼레이션 가역적 열 겔화 성질을 갖는 생분해성 저분자량 트리블럭폴리(락티드-코-글리콜리드) 폴리에틸렌 글리콜 공중합체
EP1066028A2 (en) * 1998-03-02 2001-01-10 Applied Vaccine Technologies Corp. Methods and devices for modulating the immune response
WO1999044583A2 (en) * 1998-03-02 1999-09-10 Applied Vaccine Technologies Corp. Methods and devices for modulating the immune response
US6841617B2 (en) * 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
WO2001039800A2 (en) * 1999-12-06 2001-06-07 The Board Of Trustees Of The University Of Arkansas Controlled delivery of antigens
EP1283851B1 (en) 2000-05-26 2012-03-28 Immunex Corporation Use of il-4r antibodies and compositions thereof
WO2002004009A2 (en) 2000-07-12 2002-01-17 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
US20030003074A1 (en) 2001-06-14 2003-01-02 Macromed, Inc. Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
ATE378427T1 (de) 2005-10-17 2007-11-15 Rina Netzwerk Rna Technologien Verfahren zur bestimmung einer unbekannten pns seqenz und seine verwendungen
MX2008008968A (es) * 2006-01-11 2008-09-10 Aerovance Inc Metodos y composiciones para tratar asma en primates humanos y no humanos.
BRPI0817664A2 (pt) * 2007-10-12 2015-03-24 Massachusetts Inst Technology Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
WO2009081201A2 (en) 2007-12-21 2009-07-02 Medimmune Limited BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Rα) - 173
MY153852A (en) * 2009-01-28 2015-03-31 Novartis Ag Galenic formulations of organic compounds
JP5656370B2 (ja) 2009-07-01 2015-01-21 キヤノン株式会社 画像処理装置、画像処理システム、画像処理方法、およびプログラム

Also Published As

Publication number Publication date
EP2596802A1 (en) 2013-05-29
WO2013075846A1 (en) 2013-05-30
US20140335162A1 (en) 2014-11-13
BR112014012277A2 (pt) 2019-09-24
US20180117143A1 (en) 2018-05-03
CN104039349A (zh) 2014-09-10

Similar Documents

Publication Publication Date Title
IN2014DN03429A (enrdf_load_stackoverflow)
PH12017501306A1 (en) Inhibitors of histone demethylases
PH12013501842A1 (en) Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor
CO6771409A2 (es) Acidos 1-bencilcicloalquilcarboxilicos sustituidos y su uso
PH12012502161A1 (en) Pharmaceutical formulations comprising pioglitazone and linagliptin
PH12014501984A1 (en) Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor
PH12012500632B1 (en) Pharmaceutical compositions comprising bi-1356 and metformin
EP3354640A3 (en) Mif inhibitors and their uses
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
PH12012502162A1 (en) Combination therapy
MX2011008171A (es) Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma.
BR112012032816A2 (pt) composição farmacêutica de liberação controlada, e, métodos para reduzir o efeito alimentar de uma composição de liberação controlada, reduzir o período de tempo necessário para que seja alcançado um estado estável para a metformina, para aperfeiçoar a biodisponibilidade de uma forma de dosagem de liberação controlada de matriz
UY31228A1 (es) Ariloxazoles sustituidos y su uso
MX345777B (es) Formulaciones de tabletas bicapa.
GB2503066B (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
TN2011000471A1 (en) Pharmaceutical composition presenting anti-inflammatory properties
BR112015011430A2 (pt) composição para liberação imediata e prolongada
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
GB2497453B8 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
CL2013001482A1 (es) Compuestos derivados de 3-metil-7-oxo-4-tia-1-aza-biciclo[3.2.0]heptano para utilizarse en la inhibicion de beta-lactamasas producidas por bacterias y restaurar/potenciar la actividad de antibioticos; y composicion farmaceutica que los comprende.
PH12013501896A1 (en) Use of a sprayable composition comprising ambroxol
CL2010000899A1 (es) N1-bencil-n8-hidroxi octanodiamida; composicion farmaceutica que comprende a dicho compuesto; combinacion farmaceutica que comprende a dicho compuesto; y su uso en el tratamiento de tumores.(divisional de la solicitud 1247-04).
SA515360233B1 (ar) مثبطات إنزيمات هستون ديميثيلاز
GEP201706680B (en) Catechol o-methyltransferase activity inhibiting compounds
HK1178075A (en) Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof